1. Pink Sheet
  2. >>Agency Leadership
  3. >>US FDA

US FDA Tiptoes Further Into Off-Label Use Discussions With CURE ID App

 
• By Derrick Gingery

App allows clinicians to discuss off-label treatments, but information is intended to be hypothesis-generating, not for regulatory use.

Render illustration of computer keyboard; with the print OFF-LABEL on a red button; and a small bottle of pillls.
Clinicians and non-clinicians may join the CURE ID app community and post case reports. • Source: Shutterstock

A US FDA-sanctioned smart phone app and website are allowing discussions of off-label uses for drugs, another step into the breech for an agency that traditionally has preferred not to engage in the area.

The US Food and Drug Administration and National Institutes of Health's National Center for Advancing Translational Sciences (NCATS) developed and recently released the CURE (Challenging Cases, Innovative Treatments) ID app...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from US FDA

More from Agency Leadership

Drug, Biologic Policy Staff Return To US FDA, As RIF Process Hangs In Legal Limbo

 
• By Sarah Karlin-Smith

The FDA employees with reduction-in-force notice rescissions include some who work on user fee negotiations, but staff still subject to RIFs will not officially separate from the agency this week due to ongoing legal challenges.

Pink Sheet Podcast: US FDA’s Private Pharma CEO Tour, HHS Changes COVID-19 Vaccine Advice

 
• By Derrick Gingery, Sarah Karlin-Smith, Sue Sutter, and Nielsen Hobbs

Pink Sheet reporter and editors consider the issues that could emerge during upcoming private FDA forums with pharma CEOs, as well as the impact of the surprising move by HHS Secretary Robert F. Kennedy Jr. to limit the CDC recommendation for annual COVID-19 vaccine boosters.

‘The Question Is, What’s Going To Happen Next?’ – The Future For Biosimilars In Europe

 
• By Dave Wallace

With European biosimilars developers buoyed by recent regulatory moves, Medicines for Europe’s Isabell Remus and Julie Maréchal-Jamil discuss the next steps forward for the industry.